On the ~1 year anniversary of QIAGEN’s putative sales of its ~$100M bioinformatics arm for ~$1B, which obviously did not occur, the NGS bioinformatics landscape continues to increase in relevance. Rishikesh Kayathi's latest analysis from our Clinical NGS DxBook highlights the evolving preferences and practices of labs nationwide. Dive into our newest carousel to discover:
1. Preference for Commercial Bioinformatics Solutions: Labs are voting with their testing volumes, favoring commercial pipelines for their secondary analysis needs. Interestingly, the larger, more advanced institutions utilize either in-house and / or multiple pipelines to handle complex panels.
2. Vertical Integration and Market Fragmentation: While instrument manufacturers (i.e., Illumina and ThermoFisher) enjoy the benefits of vertical integration, the secondary analysis market remains a battleground for diversity and innovation, including many in-house solutions.
3. The Future of Secondary Analysis: The race is on for leaders who can deliver a trifecta of cost-efficiency, fast turnaround time (TAT), and user-friendliness. As labs navigate the complexities of plex and panel intricacy, commercial pipelines are poised to dominate, with potential market shake-ups on the horizon.
The importance of TAT and insights from an increasingly complex set of biomarkers for diagnosis continue to increase. As a result, commercial solutions are increasingly well-equipped to serve the market. Who will win? Time will tell, but one thing's for certain: the bioinformatics field is unstoppable. Feel free to ping / DM us to discuss!
#NGSisUnstoppable #Bioinformatics
.png)
.png)
